Background: The first-line treatment of diffuse large B-cell lymphoma (DLBCL) is the combination of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, curing approximately 60% of patients. Many clinical trials have been carried out over the last 10 years trying to improve the results of this treatment, but the appropriateness of their planning strategies could be rediscussed.
Introduction
First-line treatment for diffuse large B-cell lymphoma (DLBCL) [1] is based on the combination of the anti-CD20 monoclonal antibody rituximab (R) with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The addition of R to CHOP significantly improved treatment outcome [2] [3] [4] , but 30%-40% of patients are still not cured.
To improve results, different strategies have been evaluated, including intensification of first-line chemotherapy [5] [6] [7] , consolidation with autologous stem cell transplantation (ASCT) for high-risk patients [8] [9] [10] [11] and maintenance treatment following induction [12] [13] [14] [15] [16] . In addition, over the last years, several nonchemotherapeutic agents have been added to R-CHOP in large phase III trials. Moreover, potential biomarkers, which may help risk stratification and treatment assignment (Table 1) , have been identified but their implementation in clinical trials has been inconsistent and will require further validation .
Despite initial optimism, none of the phase III trials testing the inclusion of targeted agents in the front-line regimen led to practice changing results and R-CHOP remains the standard first-line therapy.
While awaiting results of ongoing phase III trials, we carried out a retrospective review of completed phase III trials which incorporated non-chemotherapeutic agents into the R-CHOP regimen or given as maintenance following induction in treatment-naïve DLBCL patients. We also included phase III trials which substituted R with novel monoclonal antibodies. For each phase III trial, we reviewed the preceding phase I and phase II trials testing these new compounds, aiming to evaluate the evidence which supported further clinical development.
Methods
We carried out a systematic review of phase III studies performed in patients with untreated DLBCL and published in paper or abstract form which evaluated either the addition of a nonchemotherapy agent to the R-CHOP regimen, the replacement of R with other monoclonal antibodies or the addition of a small molecule as maintenance after R-CHOP. We did not include new combinations which changed the structure of the CHOP regimen, phase III trials of second or further treatment lines, or trials which explored R biosimilars, or radioimmunotherapy. We also excluded studies which explored ASCT in first remission.
We carried out a search on Pubmed using appropriate search terms (diffuse large B-cell lymphoma) AND (clinical trial). We also carried out a search for abstracts published in the last 4 years in the main hemato-oncology meetings.
The trial design, primary end point, number of patients enrolled, patient selection criteria, treatment schedule and results were registered for each phase III trial. In addition, we retrospectively searched for the phases I and II studies previously evaluating the safety and efficacy of the new compound, recording the same variables for each one.
Results
We identified eight phase III trials, six with published results (Table 2 ) and two ongoing with no preliminary data. A total of 5273 patients were enrolled in the 6 completed trials. Here we report results from the six completed phase III and their preceding phases I and II trials.
Novel monoclonal antibodies
Obinutuzumab. Obinutuzumab, a type II anti-CD20 monoclonal antibody, was evaluated in a phase III trial in previously untreated DLBCL patients. The GOYA trial randomized 1418 patients with an International Prognostic Index (IPI) score of 2, IPI ¼ 1 (if not due to age alone) or IPI ¼ 0 with bulky disease between R or obinutuzumab together with CHOP. Obinutuzumab was administered at a flat dose of 1000 mg on days 1, 8 and 15 of cycle 1, and day 1 of cycles 2-8 every 21 days. Primary end point was progression-free survival (PFS). Results were recently published, showing no benefit in the experimental arm [43, 44] , with a 3-year PFS of 70% in the G-CHOP arm versus 67% in the R-CHOP arm (P ¼ 0.39). In addition, the PET-assessed overall response rate (ORR) for the G-CHOP and R-CHOP arms were 77% and 78% and complete remission (CR) rates 57% and 60%, respectively. A higher rate of grade 3 adverse events (AEs) and serious adverse events (SAEs) were reported in the experimental arm (74% versus 65% and 43% versus 38%, respectively).
We identified two phase II trials which evaluated obinutuzumab in patients with DLBCL. The GAUGUIN trial [45] evaluated obinutuzumab monotherapy in 25 patients with DLBCL, among other histologies. These patients were randomized to eight cycles of obinutuzumab at 400/400 mg or 1600/800 mg, given on days 1 and 8 of cycle 1, and day 1 of subsequent cycles. Primary end point was ORR, defined as end-of-treatment response (ETR) rate and best ORR. ETR was 30% and 27% in the 400/400 mg and in the 1600/800 mg study arms, respectively, and best ORR was 30% in the 400/400 mg and 33% in the 1600/ 800 mg arm.
Only one phase II trial evaluated obinutuzumab in combination with CHOP in treatment-naïve DLBCL patients: the GATHER trial [46] treated 80 high-risk patients (IPI 2 or any IPI if bulky disease) with obinutuzumab at a flat dose of 1000 mg on days 1, 8 and 15 of cycle 1, and day 1 of cycles 2-8, with CHOP for six cycles. INV, investigator assessed; DFS, disease-free survival; PFS, progression-free survival; EFS, event-free survival; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; GCB, Germinal Center-B; ABC, Activated B-Cell; GEP, Gene expression profiling; PFS30, Progression-free survival at 30 months.
The ORR and CR rates were 83% and 55%, respectively. No unexpected safety signals were identified. These data do not substantially differ from the results of R-CHOP [4, 47, 48] .
Bevacizumab. The antivascular endothelial growth factor monoclonal antibody bevacizumab was evaluated in previously untreated DLBCL patients with IPI 0-5 in the MAIN phase III trial [49] , which randomized 787 patients between R-CHOP or R-CHOP þ bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks). Patients in CR after combination therapy could continue with bevacizumab maintenance every 3 weeks until month 12. Even though the initial primary end point was PFS, after observing increased cardiotoxicity without prolonged PFS in the experimental arm, the study was stopped early and the protocol was amended to include safety analysis at follow-up as the revised primary end point. Median PFS in the R-CHOP arm was 42.9 months versus 40.2 months in the experimental arm (P ¼ 0.49). The proportion of patients with grade 3/4 or grade 5 AEs was higher in the experimental arm (58% versus 55% and 8% versus 5%, respectively), just as were SAEs (57% versus 45%) and AEs of special interest related to bevacizumab, such as bleeding, congestive heart failure and hypertension(47% versus 25%). We identified three previous phase II trials, while a fourth was prematurely closed after including seven patients, when unpublished results of the cardiac AEs from the MAIN trial became available [50] .
The first trial treated 13 newly diagnosed DLBCL patients with bevacizumab (15 mg/kg on day 1 of each cycle) in association with R-CHOP. Primary end point was preliminary data on safety and efficacy. The authors concluded favorably, with an observed ORR and CR of 85% and 38%, respectively [51] .
A second phase II trial included 30 relapsed/refractory DLBCL patients, along with other histologies, treated with bevacizumab monotherapy (10 mg/kg every 2 weeks). Although well tolerated, it showed limited single agent activity with a 6-month PFS (primary end point) of 16% [52] .
The largest phase II trial included 64 newly diagnosed, advanced stage, DLBCL patients treated with bevacizumab combined with R-CHOP. The primary end point was not met, with a 1-year PFS of 77% (similar to historical R-CHOP data). Additionally, the combination showed increased hematologic and bevacizumab-related AEs [53] , with 5 cases of gastrointestinal perforation, 4 thrombotic events, and 11 patients with grade 2 or 3 left ventricular dysfunction. The MAIN trial began accrual before completion of this phase II trial.
Molecularly targeted agents
One trial assessed the addition of a molecularly targeted agent (MTA) to R-CHOP chemotherapy and three trials used an MTA as maintenance therapy after R-CHOP.
Bortezomib. The REMoDL-B phase III trial [54, 55] explored the combination of R-CHOP with the NF jB inhibitor bortezomib in treatment-naïve DLBCL patients. Patients received a first cycle of R-CHOP while their neoplastic tissue was analyzed for cell-of-origin (COO) subtype using gene expression profiling (GEP), in order to minimize the diagnosis-to-treatment interval. Those who were Germinal Center B-Cell (GCB), Activated B-Cell (ABC) or unclassifiable were randomized to R-CHOP 6 bortezomib (1.3 mg/m 2 i.v. or 1.6 mg/m 2 s.c. days 1 and 8 for cycles 2-6), while those who failed the COO determination were excluded from the study.
The study registered 1076 patients (GCB: 44.1%; ABC: 22.7%; unclassified: 18.5%; no profile: 14.6%, the latter excluded from the analysis) of all stages and IPI scores. Results on the primary end point of the study were presented at the 14th International Conference on Malignant Lymphoma (ICML) meeting in June 2017 in Lugano. No difference in PFS was observed in the combined GCB and ABC population between RB-CHOP and R-CHOP (P ¼ 0.225); PFS at 30 months (PFS30) was 74.3% and 70.1%, respectively. There were no significant differences in PFS in the GCB (PFS30 75.8% versus 72.9%; P ¼ 0.458) or ABC patients (PFS30 71.5% versus 64.7%; P ¼ 0.309), when analyzed separately. In an exploratory subgroup analysis, only ABC patients with low IPI showed a significantly better PFS with RB-CHOP treatment.
We identified seven phase I/II clinical trials that evaluated bortezomib in DLBCL. Two were phase I trials: one evaluated the addition of bortezomib to R-CHOP in untreated DLBCL and mantle-cell lymphoma (MCL) patients and established a recommended phase II dose (RP2D) of 1.3 mg/m 2 on days 1 and 4 of bortezomib with R-CHOP [56] ; the second trial evaluated bortezomib as single agent and in combination with DA-EPOCH in 49 patients with relapsed/refractory or de novo DLBCL. Based on GEP or immunohistochemistry (carried out in a minority of patients) the authors concluded that bortezomib, added to DA-EPOCH, seemed beneficial in the ABC subtype [57] .
Among five phase II studies of bortezomib added to R-CHOP, two were single arm. In the GELA group study, 49 patients (16 with newly diagnosed DLBCL or transformed follicular lymphoma) received one of two different bortezomib schedules in combination with R-CHOP. The CR rate (primary end point) was 88% (14/16) for DLBCL and transformed follicular lymphoma [58] . In the trial by Ruan et al., patients with DLBCL (n ¼ 40) or MCL (n ¼ 36) were treated with escalating doses of bortezomib and R-CHOP. Two-year PFS, the primary end point in the phase II portion of the study, was 64% in the DLBCL population. Similar outcomes were reported in patients with GCB and non-GCB subtypes based on immunohistochemical analysis from 32 patients [59] .
Three more recent phase II trials randomized newly diagnosed DLBCL patients between R-CHOP or R-CHOP þ bortezomib (two of the trials omitted vincristine in the experimental arm).
In the trial carried out by the Spanish GELTAMO group, 121 patients were randomized to R-CHOP or BRCAP (bortezomib, R, cyclophosphamide, doxorubicin and prednisone). No differences were found between the two treatment groups in terms of CR or event-free survival (the latter being the primary end point). The authors reported a subgroup analysis in non-GCB patients (n ¼ 29), showing a significantly better CR rate in the experimental arm [60] . The other two trials focused on non-GCB patients. Leonard et al. randomized 206 patients with newly diagnosed non-GCB DLBCL to R-CHOP or R-CHOP plus bortezomib, with similar PFS in the two treatment arms [61] . Finally, in the LYM-2034 study, including 164 newly diagnosed DLBCL patients, no difference was found in CR rate (primary end point), PFS or OS between R-CHOP and the experimental arm [62] .
Lenalidomide. The phase III REMARC trial assessed the immunomodulatory drug lenalidomide as maintenance therapy in elderly patients (60-80 years of age) who achieved PR or CR after first-line R-CHOP [63] . It randomized 650 patients to maintenance with lenalidomide (25 mg/day for 21 every 28 days) or placebo, for 2 years or until disease relapse or unacceptable toxicity. Patients with transformed lymphoma as well as patients who had small cell disease in the bone marrow were eligible (around 30% of the study population). With a median follow-up of 39 months, median PFS (primary end point) was not reached in the lenalidomide group versus 58.9 months in the placebo group (P ¼ 0.01). With a median follow-up of 52 months, OS was similar in both arms (P ¼ 0.26).
The role of lenalidomide maintenance was also investigated in phase II trials. In the study by Reddy et al., 44 patients with newly diagnosed DLBCL and IPI 3 in CR after frontline R-CHOP were randomized to lenalidomide 25 mg, for a total of 12 cycles, or lenalidomide 20 mg together with R on day 8 of odd numbered cycles, for a total of six doses. Primary end point of DFS at 1 year was 89%, with a 1-year OS of 91% [64] .
There were other studies which showed activity of lenalidomide in induction. We reviewed one phase I and four phase II trials testing lenalidomide in monotherapy (in relapsed DLBCL) or in combination with R-CHOP (in newly-diagnosed DLBCL). The phase I trial, conducted by the MAYO Clinic group, treated 24 newly diagnosed DLBCL patients with R-CHOP and lenalidomide at escalating doses. Lenalidomide was given on days 1-10 of 21-day cycles. The RP2D was 25 mg [65] . A follow-up phase II trial concluded with an EFS (primary end point) and OS at 24 months of 59% and 78%, respectively. Similar results were observed for the GCB and non-GCB subtypes with this combination [66] . The multicenter REAL07 phase I/II trial included 49 newly diagnosed elderly (60-80 years) DLBCL patients, 9 in the phase I part and 40 in the phase II. Patients received R-CHOP and lenalidomide (15 mg on days 1-14 of six 21-day cycles). Primary end point was ORR. Forty-five (42 CR and 3 PR) of 49 responded with an ORR of 92% and no unexpected toxicity [67] .
We identified two early phase II trials which treated relapsed/ refractory NHL patients with lenalidomide monotherapy. Together they treated 266 patients, 137 with DLBCL. The primary end point in both studies was ORR (19% and 28%) [68, 69] . A retrospective study with a similar design, including 65 relapsed/refractory DLBCL patients, reported an ORR of 42.2% [70] . Two other publications analyzed the efficacy of lenalidomide with R in relapsed/refractory DLBCL patients [71, 72] .
Given these results, the ongoing phase III ROBUST trial has randomized untreated ABC-type DLBCL patients, using a gene expression signature validated by Scott et al. [26] , to R-CHOP 6 lenalidomide (15 mg, days 1-14 of a 21-day cycle). Primary end point is PFS. Results are not reported yet [73] .
Enzastaurin. The phase III PRELUDE trial assessed the role of the selective protein kinase Cb inhibitor, enzastaurin, as maintenance therapy in patients with advanced stage DLBCL with IPI 3 in CR after R-CHOP. It randomized 758 patients to enzastaurin 500 mg daily or placebo for 3 years or until progressive disease (PD) or unacceptable toxicity. Primary end point was diseasefree survival (DFS). This was a negative study with a 4-year DFS of 70% versus 71% (P ¼ 0.541) [74] .
We identified two prior phase II trials in DLBCL patients. One study treated 55 relapsed/refractory patients with enzastaurin monotherapy. A prolonged FFP was seen in a small subset of patients (22% experienced FFP for two cycles and 15% for four cycles) and the drug was well-tolerated [75] . A more recent phase II trial included 100 untreated DLBCL patients with IPI 2 and randomized to R-CHOP-enzastaurin versus R-CHOP. If patients in the experimental arm responded, enzastaurin maintenance was continued at 500 mg daily until toxicity, PD, or for a maximum of 3 years. PFS, the primary end point, was not significantly prolonged in the experimental arm [76] .
Everolimus. The phase III PILLAR-2 trial assessed the mTOR inhibitor everolimus as maintenance therapy in high-risk patients (IPI 3) in CR after first-line immunochemotherapy. It randomized 742 patients to everolimus (10 mg daily) or placebo for 1 year or until PD or unacceptable toxicity. Primary end point was DFS. The study was negative, with a 2-year DFS of 77.8% with everolimus versus 77% with placebo (P ¼ 0.276) [77] .
Two preceding phase II trials in the relapsed/refractory setting were identified. The first trial included 47 DLBCL patients, for a total of 77 patients with different histologies, treated with everolimus 10 mg daily. It reported single-agent activity with an ORR of 30% (14/47) in the DLBCL population, providing proof-ofconcept that targeting the mTOR pathway was clinically relevant [78] . The other phase II trial treated 26 patients with everolimus 10 mg daily and R (weekly during cycle one and then on day one of subsequent cycles). Primary end point was ORR. This combination was well tolerated and showed and ORR of 37% (3 CR and 6 PR among 24 evaluable patients) [79] .
A more recent phase I trial treated 26 newly diagnosed DLBCL patients with the combination of R-CHOP and everolimus. The RP2D was 10 mg daily, days 1-14 every 21 days. This combination was safe and tolerable with a 96% CR rate in both GCB and non-GCB DLBCL patients. The high CR rate and durability of responses was used as rationale for the randomized phase III trial [80, 81] .
Discussion
A major effort has been carried out over the last years to improve the outcome of DLBCL patients. The improved knowledge on the biology of lymphomas, together with an expansion in preclinical research has led to trials incorporating non-chemotherapeutic compounds to R-CHOP as induction or maintenance, or the replacement of R with novel monoclonal antibodies. Unfortunately, most of the phase III studies carried out so far have been negative. This led us to question if the current methodology of drug development in DLBCL is correct and if results of the preceding phases I-II trials were robust enough to support moving to large phase III trials.
Other strategies in DLBCL, not analyzed in this review, include addition of classic chemotherapy agents to the R-CHOP backbone, such as DA-EPOCH-R [5] or R-ACVBP followed by combination consolidation chemotherapy [7] . Neither of these large randomized trials yielded practice-changing results.
The REMARC trial, exploring the role of lenalidomide maintenance, is the only phase III which reached its primary end point (PFS) [63] . However, this study only included patients older than 60, in PR or CR after induction treatment, showed no prolonged OS in the lenalidomide arm and a similar PR to CR conversion rate in both arms. Also, considering that close to 30% of patients were not known to have de novo DLBCL, this could have impacted outcome, as maintenance is known to prolong PFS in indolent lymphoma. It remains unclear why, with a PFS advantage, there was no OS benefit: one possible explanation is that patients progressing on lenalidomide tolerated less or had inferior responses to subsequent therapies [82] .
Other attempts to improve outcome with maintenance, including enzastaurin, everolimus and rituximab, have been unsuccessful. Rituximab was the first one explored in this setting, with many prospective randomized trials failing to show an improved outcome [12, 13] . In the pivotal trial reported by Habermann et al., R maintenance only improved failure-free survival in patients who had not received R in induction. Haioun et al. randomized high-risk patients after induction and first-line ASCT to R maintenance or observation. EFS at 4 years was not significantly increased with R maintenance. In the NHL13 study, R maintenance improved EFS, but not OS [15] . In the HD2002 prospective phase III trial, 152 patients were randomized to R maintenance versus observation after standard induction, with benefit only for the male subgroup [16] . It is possible that maintenance therapy arrives too late to save the refractory and early relapsed patients. Other agents are being tested in ongoing phase II clinical trials in the maintenance setting following front-line chemoimmunotherapy (NCT01965977, NCT02623010).
The combination of chemotherapy with obinutuzumab showed an acceptable toxicity profile in the phase II GATHER study [46] . This, together with the preclinical data showing greater direct cell death induction and antibody-dependent cellular cytotoxicity for obinutuzumab versus R, was the rationale supporting the largest phase III clinical trial carried out in DLBCL patients, the GOYA trial [44] , which did not meet its primary end point. Other monoclonal antibodies, such as ofatumumab, have also been included in clinical trials for DLBCL, but there is no phase III trial in the frontline setting [83, 84] .
With regard to phase II trials, we identified 22 trials that evaluated the 6 compounds entered in phase III trials. In particular, lenalidomide was evaluated in seven trials, bortezomib in five trials, bevacizumab in four trials, and obinutuzumab, enzastaurin, and everolimus in two trials each. These trials were very heterogeneous in inclusion criteria, treatment design and efficacy end points. Only 13 were performed in untreated DLBCL patients, of these, 5 were randomized and 8 single arm trials (Table 3) . Primary end points were time-related (PFS and EFS) in seven trials, CR rate in three trials, ORR in one and safety evaluation in two trials. This highlights the absence of standardized criteria in the design of phase II trials. Many of these concluded that the study drug combination had promising results and encouraged further trials with these agents, failing to predict the negative results later obtained in the phase III.
On the other hand, there were some clearly negative phase II trials with bortezomib [60] [61] [62] , due to lack of increased efficacy, and bevacizumab, due to increased toxicity, but phase III trials were carried out. The MAIN trial, combining bevacizumab with R-CHOP, began recruiting before the results of the SWOG 0515 phase II trial were published [53] , which led to two overlapping studies which eventually showed the same toxicity profile and reported the same negative results [49] .The evidence of activity and safety of bevacizumab in DLBCL patients for the phase III trial was based on two phase II trials, only one of which treated newly diagnosed patients with bevacizumab in combination with R-CHOP (n ¼ 13) [51, 52] .
Enzastaurin maintenance was also explored in overlapping randomized phases II and III trials [76] . The phase III PRELUDE trial [74] was based on preclinical data and the single-arm phase II trial evaluating enzastaurin monotherapy in relapsed refractory DLBCL patients [75] . The above reported examples represent a clear disconnect between results of phase II and phase III trials and highlight the requirement that results of early phase trials are analyzed before proceeding to phase III studies.
Learning from previous DLBCL trials, recent phase III trials have incorporated molecular selection for COO assessment, a more robust measure than immunohistochemistry, in order to focus on the subpopulation with highest chance of benefitting. This was not the case with some of the earlier studies, and it may have impacted results, together with the small number of patients usually included and analyzed in phase I/II trials. This novel method, however, could delay initiation of therapy and run the risk of selection bias, failing to include some of the patients with worse performance status.
Two ongoing phase III studies without reported results are the ROBUST trial, assessing the benefit of lenalidomide added to R-CHOP in ABC DLBCL patients, and the PHOENIX trial, evaluating the addition of the BTK inhibitor ibrutinib to R-CHOP in untreated non-GCB DLBCL patients [85] . This last trial was only preceded by a phase Ib study, which established the RP2D of ibrutinib with R-CHOP [85] . While the possibility of directly jumping from phase Ib trials to phase III is exploratory, and may spare time in the evaluation of a new combination, there is a risk of underestimating the toxicities and overestimating the preliminary efficacy before moving to a larger randomized trial.
Our review highlights the fact that the classical path of drug development has been a story of failure in DLBCL. In particular, it draws attention to the absence of standard end points in phase II trials before moving to phase III. EFS24 has been proposed as an accurate time-related end point in DLBCL [86] and could be further implement into future clinical trials, together with new end points including minimal residual disease [30, 31] . Finally, the implementation of modern methodologies of drug development including seamless adaptive designs, which combine all phases in one large trial, could be explored in future clinical trials in DLBCL [87] .
Conclusion
An important number of patients and resources were invested into large phase III studies integrating new drugs into the R-CHOP regimen but, up to now, none of these have changed the standard of care in DLBCL. R-CHOP induction, without maintenance, remains the first-line treatment of choice. Phases I and II trials preceding the larger phase III were unable to predict results and a methodological question may be key in this argument. We have reported a large diversity in the design, number of patients and primary end points of phases I and II clinical trials in DLBCL and the absence of standardized criteria for phase II before moving to phase III trials. The recognition of the molecular heterogeneity of DLBCL and the new tools to choose the correct patients for a novel treatment, together with the modern methodologies for drug development, may open up additional options for clinical trial design in DLBCL.
